Xencor: 'Strong Buy' On Positive XmAb819 ESMO Data ccRCC And Potential For FDA Accelerated Approval PathwaySeeking Alpha • Monday
Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney CancerMarketBeat • Monday
Xencor, Inc. (XNCR) Discusses Phase 1 XmAb819 Results in Advanced Clear Cell Renal Cell Carcinoma TranscriptSeeking Alpha • Monday
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ TumorsBusiness Wire • 10/25/26
Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell CarcinomaBusiness Wire • 10/19/26
Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty MatterBusiness Wire • 07/29/26
Xencor: Strong Buy, XmAb819 Presentation, And End Of 2026 XmAb942 Interim DataSeeking Alpha • 07/20/26
Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell CarcinomaBusiness Wire • 07/17/26
Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/13/26
Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 TranscriptSeeking Alpha • 05/05/26
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDWBusiness Wire • 05/04/26
Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/11/26